Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review

Pharmacological Research

Volumn 62, Issue 3, 2010, Pages 187-206

  Repantis, Dimitris ^a   Schlattmann, Peter ^a   Laisney, Oona ^a   Heuser, Isabella ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cognitive enhancement; Cognitive performance; Enhancement; Healthy young adults; Methylphenidate; Modafinil; Neuroenhancement; Neuroethics; Sleep deprivation; Systematic review

Indexed keywords

METHYLPHENIDATE; MODAFINIL; PLACEBO; BENZHYDRYL DERIVATIVE; CENTRAL STIMULANT AGENT;

ABDOMINAL PAIN; ALERTNESS; ANXIETY; ATTENTION; BRAIN FUNCTION; CLINICAL TRIAL; COGNITION; DIURESIS; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG INDUCED HEADACHE; DRUG MEGADOSE; EMOTION; EVENING DOSAGE; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HUMAN; HYPERTENSION; INSOMNIA; LEARNING; MEMORY; MENTAL FUNCTION; META ANALYSIS; MORNING DOSAGE; MOTIVATION; NAUSEA; NERVOUSNESS; PRIORITY JOURNAL; RESTLESSNESS; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DEPRIVATION; SLEEP DISORDER; SYSTEMATIC REVIEW; TACHYCARDIA; WAKEFULNESS; XEROSTOMIA; ANIMAL; DRUG EFFECTS;

ANIMALS; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITION; EMOTIONS; HUMANS; METHYLPHENIDATE; MOTIVATION;

EID: 77954216118     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2010.04.002     Document Type: Review

References (82)

1. Schöne-Seifert B., Talbot D. (Neuro-)enhancement. Textbook of Psychiatry 2009, Springer, New York. H. Helmchen, N. Sartorius (Eds.).
2. Larriviere D., Williams M.A., Rizzo M., Bonnie R.J. Responding to requests from adult patients for neuroenhancements: guidance of the Ethics, Law and Humanities Committee. Neurology 2009, 73:1406-1412.
3. Talbot M. Brain gain 2009, The New Yorker.
4. de Jongh R., Bolt I., Schermer M., Olivier B. Botox for the brain: enhancement of cognition, mood and pro-social behavior and blunting of unwanted memories. Neurosci Biobehav Rev 2008, 32:760-776.
5. Sahakian B., Morein-Zamir S. Professor's little helper. Nature 2007, 450:1157-1159.
6. The Economist. All on the mind. The Economist 2008
7. McCabe S.E., Knight J.R., Teter C.J., Wechsler H. Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction 2005, 100:96-106.
8. Maher B. Poll results: look who's doping. Nature 2008, 452:674-675.
9. DAK-Gesundheitsreport. Schwerpunktthema Doping am Arbeitsplatz 2009;37-91.
10. Mehlman M. Cognition-enhancing drugs. Milbank Quart 2004, 82:483-506.
11. Physicians' desk reference. Physicians' desk reference. 63rd ed. Montvale, NJ: Thomson Reuters; 2009.
12. Gould M.S., Walsh B.T., Munfakh J.L., Kleinman M., Duan N., Olfson M., et al. Sudden death and use of stimulant medications in youths. Am J Psychiatry 2009, 166:A16.
13. Sulzer D., Sonders M.S., Poulsen N.W., Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 2005, 75:406-433.
14. Volkow N.D., Fowler J.S., Logan J., Alexoff D., Zhu W., Telang F., et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 2009, 301:1148-1154.
15. Minzenberg M.J., Carter C.S., Modafinil: A review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008, 33(7):1477-1502.
16. Ballon J.S., Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatr 2006, 67:554-566.
17. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Control Clin Trials 1996, 17:1-12.
18. Dumont G.J., de-Visser S.J., Cohen A.F., van-Gerven J.M. Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects. Br J Clin Pharmacol 2005, 59:495-510.
19. Spreen O., Strauss E. A compendium of neuropsychological tests; administration, norms, and commentary 1998, Oxford University Press, Inc., New York. 2nd ed.
20. Cohen J. Statistical power analysis for the behavioral sciences 1988, Academic Press, New York.
21. Rogers N.L., Maislin G., Van Dongen H.P., Dinges D.F. Neurobehavioural and physiological outcomes from modafinil during severe sleep loss (abstract). Int Med J 2004, 34:A19.
22. Wesnes K.A., Macher J.P. Modafinil reverses the marked attentional deficits produced by acute sleep deprivation in healthy volunteers. Eur Neuropsychopharm 2004, 14:S380.
23. Li Y.F., Zhan H., Xin Y.M., Tang G.X., Wei S.H., et al. Effects of modafinil on visual and auditory reaction abilities and subjective fatigue level during 48h sleep deprivation. Space Med Med Eng (Beijing) 2003, 16:277-280.
24. Caldwell J.A., Caldwell J.L., Smythe N.K., Hall K.K. A double-blind, placebo-controlled investigation of the efficacy of modafinil for sustaining the alertness and performance of aviators: a helicopter simulator study. Psychopharmacology (Berl) 2000, 150:272-282.
25. Caldwell J.A., Caldwell J.L., Smith J.K., Brown D.L. Modafinil's effects on simulator performance and mood in pilots during 37h without sleep. Aviat Space Environ Med 2004, 75:777-784.
26. Eddy D, Storm W, French J, Barton E, Cardenas R. An assessment of modafinil for vestibular and aviation-related effects. AFRL-HE-BR-TR-2005-0129 ed. United States Air Force Research Laboratory; 2005.
27. Whitmore J, Doan B, Heintz T, Hurtle W, Kisner J, Smith JK. The efficacy of modafinil as an operational fatigue countermeasure over several days of reduced sleep during a simulated escape and evasion scenario. AFRL-HE-BR-TR-2004-0021 ed. United States Air Force Research Laboratory; 2004.
28. Whitmore J, Hickey P, Doan B, Harrison R, Kisner J, Beltran T, et al. A double-blind placebo controlled investigation of the efficacy of modafinil for maintaining alertness and performance in sustained military ground operations. AFRL-HE-BR-TR-2006-0005 ed. United States Air Force Research Laboratory; 2006.
29. Bonnet M.H., Balkin T.J., Dinges D.F., Roehrs T., Rogers N.L., Wesensten N.J. The use of stimulants to modify performance during sleep loss: a review by the sleep deprivation and Stimulant Task Force of the American Academy of Sleep Medicine. Sleep 2005, 28:1163-1187.
30. Babkoff H., Kelly T., Matteson L., Gomez S., Lopez A., Hauser S., et al. Pemoline and methylphenidate: interaction with mood, sleepiness, and cognitive performance during64 hours of sleep deprivation. Mil Psychol 1992, 4:235-265.
31. Bishop C., Roehrs T., Rosenthal L., Roth T. Alerting effects of methylphenidate under basal and sleep-deprived conditions. Exp Clin Psychopharm 1997, 5:344-352.
32. Gilbert J.G., Donnelly K.J., Zimmer L.E., Kubis J.F. Effect of magnesium pemoline and methylphenidate on memory improvement and mood in normal aging subjects. Int J Aging Hum Dev 1973, 4:35-51.
33. Gobbi G., Slater S., Boucher N., Debonnel G., Blier P. Neurochemical and psychotropic effects of bupropion in healthy male subjects. J Clin Psychopharm 2003, 23:233-239.
34. Bray C.L., Cahill K.S., Oshier J.T., Peden C.S., Theriaque D.W., et al. Methylphenidate does not improve cognitive function in healthy sleep-deprived young adults. J Invest Med 2004, 52:192-201.
35. Roehrs T., Papineau K., Rosenthal L., Roth T. Sleepiness and the reinforcing and subjective effects of methylphenidate. Exp Clin Psychopharm 1999, 7:145-150.
36. Roehrs T., Meixner R., Turner L., Johanson C.E., Roth T. Reinforcing and subjective effects of methylphenidate: dose and time in bed. Exp Clin Psychopharm 2004, 12:180-189.
37. Smith D., Pernet A., Rosenthal J.M., Bingham E.M., Reid H., Macdonald I.A., et al. The effect of modafinil on counter-regulatory and cognitive responses to hypoglycaemia. Diabetologia 2004, 47:1704-1711.
38. Taneja I., Haman K., Shelton R.C., Robertson D. A randomized, double-blind, crossover trial of modafinil on mood. J Clin Psychopharm 2007, 27:76-79.
39. Baranski J.V., Pigeau R., Dinich P., Jacobs I. Effects of modafinil on cognitive and meta-cognitive performance. Hum Psychopharmacol Clin Exp 2004, 19:323-332.
40. Babkoff H., Krueger G. Use of stimulants to ameliorate the effects of sleep loss during sustained performance. Mil Psychol 1992, 4:191-205.
41. Dinges D.F., Arora S., Darwish M., Niebler G.E. Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss. Curr Med Res Opin 2006, 22:159-167.
42. Balanza-Martinez V., Rubio C., Selva-Vera G., Martinez-Aran A., Sanchez-Moreno J., Salazar-Fraile J., et al. Neurocognitive endophenotypes (endophenocognitypes) from studies of relatives of bipolar disorder subjects: A systematic review. Neurosci Biobehav Rev 2008, 32:1426-1438.
43. Repantis D., Schlattmann P., Laisney O., Heuser I. Antidepressants for neuroenhancement in healthy individuals: a systematic review. Poiesis Prax 2009, 6:139-174.
44. Geen R. Human motivation: a psychological approach 1994, Wadsworth Publishing, Belmont.
45. Coull J.T. Neural correlates of attention and arousal: insights from electrophysiology, functional neuroimaging and psychopharmacology. Progr Neurobiol 1998, 55:343-361.
46. Amado-Boccara I., Gougoulis N., Littre M.F.P., Galinowski A., Loo H. Effects of antidepressants on cognitive functions: a review. Neurosci Biobehav Rev 1995, 19:479-493.
47. Rose S.P. 'Smart drugs': do they work? Are they ethical? Will they be legal?. Nat Rev Neurosci 2002, 3:975-979.
48. Schmitt J.A.J., Wingen M., Ramaekers J.G., Evers E.A.T., Riedel W.J. Serotonin and human cognitive performance. Curr Pharmaceut Des 2006, 12:2473-2486.
49. Farah M.J., Illes J., Cook-Deegan R., Gardner H., Kandel E., King P., et al. Neurocognitive enhancement: what can we do and what should we do?. Nat Rev Neurosci 2004, 5:421-425.
50. Volkow N.D., Wang G.J., Fowler J.S., Telang F., Maynard L., et al. Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. Am J Psychiat 2004, 161:1173-1180.
51. Baranski J., Pigeau R.A. Self-monitoring cognitive performance during sleep deprivation: effects of modafinil, d-amphetamine and placebo. J Sleep Res 1997, 6:84-91.
52. Caldwell JA, Smythe NK, Caldwell JL, Hall KK, Norman DN, et al. The effects of modafinil on aviator performance during 40hours of continuous wakefulness: a UH-60 helicopter simulator study. United States Air Force Research Laboratory 1999; USAARL Report No. 99-17:.
53. Gill M., Haerich P., Westcott K., Godenick K.L., Tucker J.A. Cognitive performance following modafinil versus placebo in sleep-deprived emergency physicians: a double-blind randomized crossover study. Acad Emerg Med 2006, 13:158-165.
54. Hart C.L., Haney M., Vosburg S.K., Comer S.D., Gunderson E., Foltin R.W. Modafinil attenuates disruptions in cognitive performance during simulated night-shift work. Neuropsychopharmacol 2006, 31:1526-1536.
55. Lagarde D., Batejat D., Van-Beers P., Sarafian D., Pradella S. Interest of modafinil, a new psychostimulant, during a sixty-hour sleep deprivation experiment. Fund Clin Pharmacol 1995, 9:271-279.
56. Pigeau R., Naitoh P., Buguet A., McCann C., Baranski J., Taylor M., et al. Modafinil, d-amphetamine and placebo during 64hours of sustained mental work. I. Effects on mood, fatigue, cognitive performance and body temperature. J Sleep Res 1995, 4:212-228.
57. Wesensten N.J., Belenky G., Kautz M.A., Thorne D.R., Reichardt R.M., Balkin T.J. Maintaining alertness and performance during sleep deprivation: modafinil versus caffeine. Psychopharmacology 2002, 159:238-247.
58. Brumaghim J.T., Klorman R. Methylphenidate's effects on paired-associate learning and event-related potentials of young adults. Psychophysiology 1998, 35:73-85.
59. Clark C.R., Geffen G.M., Geffen L.B. Role of monoamine pathways in attention and effort: effects of clonidine and methylphenidate in normal adult humans. Psychopharmacology (Berl) 1986, 90:35-39.
60. Fitzpatrick P., Klorman R., Brumaghim J.T., Keefover R.W. Effects of methylphenidate on stimulus evaluation and response processes: evidence from performance and event-related potentials. Psychophysiology 1988, 25:292-304.
61. Hink R.F., Fenton W.H., Pfefferbaum A., Tinklenberg J.R., Kopell B.S. The distribution of attention across auditory input channels: an assessment using the human evoked potential. Psychophysiology 1978, 15:466-473.
62. Mehta M.A., Owen A.M., Sahakian B.J., Mavaddat N., Pickard J.D., Robbins T.W. Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neurosci 2000, 20:RC65.
63. Peloquin L.J., Klorman R. Effects of methylphenidate on normal children's mood, event-related potentials, and performance in memory scanning and vigilance. J. Abnorm Psychol 1986, 95:88-98.
64. Rogers R.D., Blackshaw A.J., Middleton H.C., Matthews K., Hawtin K., Crowley C., et al. Tryptophan depletion impairs stimulus-reward learning while methylphenidate disrupts attentional control in healthy young adults: implications for the monoaminergic basis of impulsive behaviour. Psychopharmacology 1999, 146:482-491.
65. Strauss J., Lewis J.L., Klorman R., Peloquin L.J., Perlmutter R.A., Salzman L.F. Effects of methylphenidate on young adults' performance and event-related potentials in a vigilance and a paired-associates learning test. Psychophysiology 1984, 21:609-621.
66. Volkow N.D., Wang G.J., Fowler J.S., Gatley S.J., Logan J., Ding Y.S., et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 1998, 155:1325-1331.
67. Volkow N.D., Wang G.J., Fowler J.S., Logan J., Gatley S.J., Wong C., et al. Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D2 receptors. J Pharmacol Exp Therapeut 1999, 291:409-415.
68. Volkow N.D., Wang G.J., Fowler J.S., Gatley S.J., Logan J., Ding Y., et al. Blockade of striatal dopamine transporters by intravenous methylphenidate is not sufficient to induce self-reports of 'high'. J Pharmacol Exp Therapeut 1999, 288:14-20.
69. Wetzel C.D., Squire L.R., Janowsky D.S. Methylphenidate impairs learning and memory in normal adults. Behav Neural Biol 1981, 31:413-424.
70. Egger M., Smith G.D., Altman D.G. Systematic reviews in health care: meta-analysis in context 2001, BMJ Books, London.
71. Cochrane handbook for systematic reviews of interventions 4. 2. 6 [updated September 2006] 2006, The Cochrane Library, John Wiley & Sons, Ltd, Chichester, UK, Issue 4. J. Higgins, S. Green (Eds.).
72. Elliott R., Sahakian B.J., Matthews K., Bannerjea A., Rimmer J., Robbins T.W. Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology 1997, 131:196-206.
73. Turner D.C., Robbins T.W., Clark L., Aron A.R., Dowson J., Sahakian B.J. Relative lack of cognitive effects of methylphenidate in elderly male volunteers. Psychopharmacology 2003, 168:455-464.
74. Babcock Q., Byrne T. Student perceptions of methylphenidate abuse at a public liberal arts college. J Am Coll Health 2000, 49:143-145.
75. Kollins S.H., Rush C.R., Pazzaglia P.J., Ali J.A. Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Exp Clin Psychopharmacol 1998, 6:367-374.
76. Warot D., Corruble E., Payan C., Weil J.S., Puech A.J. Subjective effects of modafinil, a new central adrenergic stimulant in healthy volunteers: a comparison with amphetamine, caffeine and placebo. Eur Psychiat 1993, 8:201-208.
77. Baranski J., Gil V., McLellan T.M., Moroz D., Buguet A., Radomski M.W. Effects of modafinil on cognitive performance during 40hr of sleep deprivation in a warm environment. Military Psychol 2002, 14:23-47.
78. Randall D.C., Shneerson J.M., File S.E. Cognitive effects of modafinil in student volunteers may depend on IQ. Pharmacol Biochem Behav 2005, 82:133-139.
79. Chatterjee A. Is it acceptable for people to take methylphenidate to enhance performance? No. BMJ 2009, 338:b1956.
80. Horn G. Brain science, addiction and drugs. An Academy of Medical Sciences working group report. Acad Med Sci 2008.
81. Greely H., Sahakian B., Harris J., Kessler R.C., Gazzaniga M., Campbell P., et al. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 2008, 456:702-705.
82. Harris J. Is it acceptable for people to take methylphenidate to enhance performance? Yes. BMJ 2009, 338:b1955.